XNAS 04 May, 2026 1:34 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| David Raben | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 27 Apr 2026 | 5,500 | 60,786 | - | 3.8 | 20,844 | Common Stock |
| David Raben | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Apr 2026 | 5,500 | 41,913 | - | - | Stock Option (Right to Buy) | |
| David Raben | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.88 per share. | 27 Apr 2026 | 5,500 | 55,286 | - | 22.9 | 125,830 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 23.00 per share. | 21 Apr 2026 | 9,200 | 145,355 | - | 23.0 | 211,614 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Apr 2026 | 9,200 | 39,744 | - | - | Stock Option (Right to Buy) | |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 21 Apr 2026 | 9,200 | 154,555 | - | 3.8 | 34,866 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2026 | 8,226 | 56,684 | - | - | Stock Option (Right to Buy) | |
| Claire Mazumdar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 23.61 per share. | 16 Apr 2026 | 15,000 | 362,152 | - | 23.6 | 354,146 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 16 Apr 2026 | 15,000 | 377,152 | - | 3.8 | 56,847 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.45 per share. | 16 Apr 2026 | 7,080 | 362,152 | - | 5.5 | 38,612 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 16 Apr 2026 | 7,454 | 355,072 | - | 3.8 | 28,249 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.44 per share. | 16 Apr 2026 | 8,226 | 347,618 | - | 4.4 | 36,498 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2026 | 15,000 | 161,107 | - | - | Stock Option (Right to Buy) | |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2026 | 7,080 | 558,432 | - | - | Stock Option (Right to Buy) | |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Apr 2026 | 7,454 | 130,546 | - | - | Stock Option (Right to Buy) | |
| Ryan Cohlhepp | Director, President and COO | Sale of securities on an exchange or to another person at price $ 23.01 per share. | 15 Apr 2026 | 8,000 | 200,641 | - | 23.0 | 184,058 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2026 | 8,000 | 109,334 | - | - | Stock Option (Right to Buy) | |
| Ryan Cohlhepp | Director, President and COO | Sale of securities on an exchange or to another person at price $ 23.01 per share. | 15 Apr 2026 | 4,500 | 196,141 | - | 23.0 | 103,533 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 15 Apr 2026 | 8,000 | 208,641 | - | 3.8 | 30,318 | Common Stock |
| David Raben | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2026 | 5,500 | 47,413 | - | - | Stock Option (Right to Buy) | |
| David Raben | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 25 Mar 2026 | 5,500 | 60,786 | - | 3.8 | 20,844 | Common Stock |
| David Raben | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.95 per share. | 25 Mar 2026 | 5,500 | 55,286 | - | 19.0 | 104,229 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 23 Mar 2026 | 9,200 | 154,555 | - | 3.8 | 34,866 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.52 per share. | 23 Mar 2026 | 9,200 | 145,355 | - | 18.5 | 170,348 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Mar 2026 | 9,200 | 48,944 | - | - | Stock Option (Right to Buy) | |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 18 Mar 2026 | 6,499 | 345,891 | - | 3.8 | 24,630 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Mar 2026 | 1,596 | 176,107 | - | - | Stock Option (Right to Buy) | |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Mar 2026 | 6,905 | 177,703 | - | - | Stock Option (Right to Buy) | |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Mar 2026 | 6,499 | 184,608 | - | - | Stock Option (Right to Buy) | |
| Claire Mazumdar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.95 per share. | 18 Mar 2026 | 1,596 | 339,392 | - | 19.0 | 30,246 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 18 Mar 2026 | 1,596 | 340,988 | - | 3.8 | 6,049 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.78 per share. | 18 Mar 2026 | 6,905 | 339,392 | - | 18.8 | 129,705 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 18 Mar 2026 | 6,905 | 346,297 | - | 3.8 | 26,169 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.84 per share. | 18 Mar 2026 | 6,499 | 339,392 | - | 18.8 | 122,415 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 16 Mar 2026 | 8,000 | 213,141 | - | 3.8 | 30,318 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Sale of securities on an exchange or to another person at price $ 19.66 per share. | 16 Mar 2026 | 4,500 | 200,641 | - | 19.7 | 88,457 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Sale of securities on an exchange or to another person at price $ 19.66 per share. | 16 Mar 2026 | 8,000 | 205,141 | - | 19.7 | 157,257 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Mar 2026 | 8,000 | 117,334 | - | - | Stock Option (Right to Buy) | |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 09 Mar 2026 | 36,766 | 376,158 | - | 3.8 | 139,336 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2026 | 36,766 | 191,107 | - | - | Stock Option (Right to Buy) | |
| Claire Mazumdar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 19.17 per share. | 09 Mar 2026 | 36,766 | 339,392 | - | 19.2 | 704,657 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 04 Mar 2026 | 2,631 | 342,023 | - | 3.8 | 9,971 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2026 | 3,817 | 227,873 | - | - | Stock Option (Right to Buy) | |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2026 | 1,786 | 231,690 | - | - | Stock Option (Right to Buy) | |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2026 | 2,631 | 233,476 | - | - | Stock Option (Right to Buy) | |
| Claire Mazumdar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.75 per share. | 04 Mar 2026 | 3,817 | 339,392 | - | 18.8 | 71,572 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 04 Mar 2026 | 3,817 | 343,209 | - | 3.8 | 14,466 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.74 per share. | 04 Mar 2026 | 1,786 | 339,392 | - | 18.7 | 33,464 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 04 Mar 2026 | 1,786 | 341,178 | - | 3.8 | 6,769 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.73 per share. | 04 Mar 2026 | 2,631 | 339,392 | - | 18.7 | 49,289 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 03 Mar 2026 | 12,892 | 222,533 | - | 3.8 | 48,858 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 12,892 | 125,334 | - | - | Stock Option (Right to Buy) | |
| Ryan Cohlhepp | Director, President and COO | Sale of securities on an exchange or to another person at price $ 18.16 per share. | 03 Mar 2026 | 4,500 | 205,141 | - | 18.2 | 81,734 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Sale of securities on an exchange or to another person at price $ 18.16 per share. | 03 Mar 2026 | 12,892 | 209,641 | - | 18.2 | 234,159 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.25 per share. | 03 Mar 2026 | 2,963 | 145,355 | - | 18.2 | 54,062 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 03 Mar 2026 | 2,963 | 148,318 | - | 3.8 | 11,229 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.22 per share. | 03 Mar 2026 | 13,555 | 145,355 | - | 18.2 | 246,910 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 03 Mar 2026 | 7,318 | 152,673 | - | 3.8 | 27,734 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 03 Mar 2026 | 6,237 | 158,910 | - | 3.8 | 23,637 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 2,963 | 79,784 | - | - | Stock Option (Right to Buy) | |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 6,237 | 82,747 | - | - | Stock Option (Right to Buy) | |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 7,318 | 58,144 | - | - | Stock Option (Right to Buy) | |
| David Raben | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 03 Mar 2026 | 16,300 | 71,586 | - | 3.8 | 61,774 | Common Stock |
| David Raben | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 03 Mar 2026 | 200 | 55,486 | - | 3.8 | 758 | Common Stock |
| David Raben | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.45 per share. | 03 Mar 2026 | 200 | 55,286 | - | 18.5 | 3,690 | Common Stock |
| David Raben | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.52 per share. | 03 Mar 2026 | 16,300 | 55,286 | - | 18.5 | 301,920 | Common Stock |
| David Raben | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 200 | 69,213 | - | - | Stock Option (Right to Buy) | |
| David Raben | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2026 | 16,300 | 52,913 | - | - | Stock Option (Right to Buy) | |
| Ryan Cohlhepp | Director, President and COO | Sale of securities on an exchange or to another person at price $ 18.04 per share. | 25 Feb 2026 | 3,108 | 210,164 | - | 18.0 | 56,067 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2026 | 3,108 | 138,226 | - | - | Stock Option (Right to Buy) | |
| Ryan Cohlhepp | Director, President and COO | Sale of securities on an exchange or to another person at price $ 18.04 per share. | 25 Feb 2026 | 523 | 209,641 | - | 18.0 | 9,435 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 25 Feb 2026 | 3,108 | 213,272 | - | 3.8 | 11,779 | Common Stock |
| Lara Meisner | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Claire Mazumdar | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 450,000 | 450,000 | - | - | Stock Option (Right to Buy) | |
| Ryan Cohlhepp | Director, President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Ivan Hyep | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| David Raben | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2026 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Ryan Cohlhepp | Director, President and COO | Sale of securities on an exchange or to another person at price $ 18.10 per share. | 22 Jan 2026 | 3,828 | 210,164 | - | 18.1 | 69,296 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 22 Jan 2026 | 1,882 | 147,237 | - | 3.8 | 7,132 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.15 per share. | 22 Jan 2026 | 1,882 | 145,355 | - | 18.2 | 34,162 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2026 | 1,882 | 65,462 | - | - | Stock Option (Right to Buy) | |
| Ryan Cohlhepp | Director, President and COO | Sale of securities on an exchange or to another person at price $ 18.02 per share. | 15 Jan 2026 | 149 | 213,992 | - | 18.0 | 2,685 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.44 per share. | 26 Dec 2025 | 25,000 | 214,141 | - | 4.4 | 110,923 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Dec 2025 | 25,000 | 39,909 | - | - | Stock Option (Right to Buy) | |
| David Raben | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Dec 2025 | 19,789 | 98,987 | - | - | Stock Option (Right to Buy) | |
| David Raben | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 26 Dec 2025 | 19,789 | 55,286 | - | 3.8 | 74,996 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2025 | 9,200 | 88,984 | - | - | Stock Option (Right to Buy) | |
| Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.31 per share. | 22 Dec 2025 | 9,200 | 145,355 | - | 18.3 | 168,492 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 22 Dec 2025 | 9,200 | 154,555 | - | 3.8 | 34,866 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Dec 2025 | 29,500 | 565,512 | - | - | Stock Option (Right to Buy) | |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.45 per share. | 16 Dec 2025 | 29,500 | 339,392 | - | 5.5 | 160,884 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Sale of securities on an exchange or to another person at price $ 18.68 per share. | 15 Dec 2025 | 8,000 | 193,641 | - | 18.7 | 149,470 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2025 | 8,000 | 141,334 | - | - | Stock Option (Right to Buy) | |
| Ryan Cohlhepp | Director, President and COO | Sale of securities on an exchange or to another person at price $ 18.68 per share. | 15 Dec 2025 | 4,500 | 189,141 | - | 18.7 | 84,077 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 15 Dec 2025 | 8,000 | 201,641 | - | 3.8 | 30,318 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 24 Nov 2025 | 41,163 | 351,055 | - | 3.8 | 156,000 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Nov 2025 | 41,163 | 236,107 | - | - | Stock Option (Right to Buy) | |
| Claire Mazumdar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.86 per share. | 24 Nov 2025 | 41,163 | 309,892 | - | 18.9 | 776,429 | Common Stock |
| David Raben | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 24 Nov 2025 | 5,500 | 40,997 | - | 3.8 | 20,844 | Common Stock |
| David Raben | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 24 Nov 2025 | 906 | 36,403 | - | 3.8 | 3,434 | Common Stock |
| David Raben | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.84 per share. | 24 Nov 2025 | 4,594 | 35,497 | - | 18.8 | 86,562 | Common Stock |
| David Raben | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 24 Nov 2025 | 4,594 | 40,091 | - | 3.8 | 17,410 | Common Stock |
| David Raben | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.45 per share. | 24 Nov 2025 | 5,500 | 35,497 | - | 18.5 | 101,475 | Common Stock |
| David Raben | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Nov 2025 | 906 | 69,413 | - | - | Stock Option (Right to Buy) | |
| David Raben | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Nov 2025 | 4,594 | 118,776 | - | - | Stock Option (Right to Buy) | |
| David Raben | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Nov 2025 | 5,500 | 123,370 | - | - | Stock Option (Right to Buy) | |
| David Raben | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.84 per share. | 24 Nov 2025 | 906 | 35,497 | - | 18.8 | 17,071 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Sale of securities on an exchange or to another person at price $ 18.05 per share. | 21 Nov 2025 | 4,500 | 193,641 | - | 18.0 | 81,212 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Sale of securities on an exchange or to another person at price $ 18.05 per share. | 21 Nov 2025 | 8,000 | 198,141 | - | 18.0 | 144,376 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 21 Nov 2025 | 8,000 | 206,141 | - | 3.8 | 30,318 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2025 | 8,000 | 149,334 | - | - | Stock Option (Right to Buy) | |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2025 | 605 | 115,979 | - | - | Stock Option (Right to Buy) | |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 21 Nov 2025 | 17,795 | 163,150 | - | 3.8 | 67,439 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.15 per share. | 21 Nov 2025 | 605 | 145,355 | - | 18.2 | 10,981 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 21 Nov 2025 | 605 | 145,960 | - | 3.8 | 2,293 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2025 | 17,795 | 98,184 | - | - | Stock Option (Right to Buy) | |
| Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.55 per share. | 21 Nov 2025 | 17,795 | 145,355 | - | 18.5 | 330,094 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 16 Oct 2025 | 24,103 | 333,995 | - | 3.8 | 91,346 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2025 | 24,103 | 277,270 | - | - | Stock Option (Right to Buy) | |
| Claire Mazumdar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.83 per share. | 16 Oct 2025 | 24,103 | 309,892 | - | 18.8 | 453,761 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Sale of securities on an exchange or to another person at price $ 18.16 per share. | 15 Oct 2025 | 4,500 | 198,141 | - | 18.2 | 81,699 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Sale of securities on an exchange or to another person at price $ 18.16 per share. | 15 Oct 2025 | 8,000 | 202,641 | - | 18.2 | 145,243 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 15 Oct 2025 | 8,000 | 210,641 | - | 3.8 | 30,318 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Oct 2025 | 8,000 | 157,334 | - | - | Stock Option (Right to Buy) | |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 13 Oct 2025 | 11,445 | 321,337 | - | 3.8 | 43,374 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2025 | 13,289 | 301,373 | - | - | Stock Option (Right to Buy) | |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2025 | 11,445 | 314,662 | - | - | Stock Option (Right to Buy) | |
| Claire Mazumdar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.84 per share. | 13 Oct 2025 | 13,289 | 309,892 | - | 18.8 | 250,391 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 13 Oct 2025 | 13,289 | 323,181 | - | 3.8 | 50,363 | Common Stock |
| Claire Mazumdar | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 18.92 per share. | 13 Oct 2025 | 11,445 | 309,892 | - | 18.9 | 216,545 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 09 Oct 2025 | 6,415 | 151,770 | - | 3.8 | 24,312 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Oct 2025 | 6,415 | 116,584 | - | - | Stock Option (Right to Buy) | |
| Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.23 per share. | 09 Oct 2025 | 6,415 | 145,355 | - | 18.2 | 116,931 | Common Stock |
| David Raben | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Oct 2025 | 22,000 | 128,870 | - | - | Stock Option (Right to Buy) | |
| David Raben | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.45 per share. | 09 Oct 2025 | 22,000 | 35,497 | - | 18.5 | 405,900 | Common Stock |
| David Raben | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 09 Oct 2025 | 22,000 | 57,497 | - | 3.8 | 83,376 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 06 Oct 2025 | 24,000 | 245,141 | - | 3.8 | 90,955 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2025 | 8,000 | 165,334 | - | - | Stock Option (Right to Buy) | |
| Ryan Cohlhepp | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2025 | 24,000 | 173,334 | - | - | Stock Option (Right to Buy) | |
| Ryan Cohlhepp | Director, President and COO | Sale of securities on an exchange or to another person at price $ 18.06 per share. | 06 Oct 2025 | 2,900 | 202,641 | - | 18.1 | 52,371 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Sale of securities on an exchange or to another person at price $ 18.06 per share. | 06 Oct 2025 | 8,000 | 205,541 | - | 18.1 | 144,473 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 06 Oct 2025 | 8,000 | 213,541 | - | 3.8 | 30,318 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Sale of securities on an exchange or to another person at price $ 18.06 per share. | 06 Oct 2025 | 15,600 | 205,541 | - | 18.1 | 281,666 | Common Stock |
| Ryan Cohlhepp | Director, President and COO | Sale of securities on an exchange or to another person at price $ 18.06 per share. | 06 Oct 2025 | 24,000 | 221,141 | - | 18.1 | 433,332 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.17 per share. | 06 Oct 2025 | 6,514 | 145,355 | - | 18.2 | 118,356 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 06 Oct 2025 | 6,514 | 151,869 | - | 3.8 | 24,687 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2025 | 5,627 | 122,999 | - | - | Stock Option (Right to Buy) | |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2025 | 18,244 | 128,626 | - | - | Stock Option (Right to Buy) | |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Oct 2025 | 6,514 | 146,870 | - | - | Stock Option (Right to Buy) | |
| Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.21 per share. | 06 Oct 2025 | 5,627 | 145,355 | - | 18.2 | 102,456 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 06 Oct 2025 | 5,627 | 150,982 | - | 3.8 | 21,325 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.22 per share. | 06 Oct 2025 | 18,244 | 145,355 | - | 18.2 | 332,386 | Common Stock |
| Ivan Hyep | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.79 per share. | 06 Oct 2025 | 18,244 | 163,599 | - | 3.8 | 69,141 | Common Stock |
| Lara Meisner | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.24 per share. | 29 Sep 2025 | 33,807 | 33,807 | - | 9.2 | 312,495 | Common Stock |
| Lara Meisner | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Sep 2025 | 33,807 | 101,423 | - | - | Stock Option (Right to Buy) | |
| Lara Meisner | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 14.75 per share. | 29 Sep 2025 | 33,807 | 0 | - | 14.7 | 498,653 | Common Stock |
| Lara Meisner | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.45 per share. | 15 Sep 2025 | 15,829 | 15,829 | - | 5.4 | 86,268 | Common Stock |
| Lara Meisner | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2025 | 9,744 | 87,699 | - | - | Stock Option (Right to Buy) | |
| Lara Meisner | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Sep 2025 | 6,085 | 54,769 | - | - | Stock Option (Right to Buy) | |
| Lara Meisner | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 11.49 per share. | 15 Sep 2025 | 15,829 | 0 | - | 11.5 | 181,875 | Common Stock |
| Lara Meisner | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 10.43 per share. | 16 Jun 2025 | 15,829 | 0 | - | 10.4 | 165,096 | Common Stock |
| Lara Meisner | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2025 | 9,744 | 97,443 | - | - | Stock Option (Right to Buy) | |
| Lara Meisner | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2025 | 6,085 | 60,854 | - | - | Stock Option (Right to Buy) | |
| Lara Meisner | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.45 per share. | 16 Jun 2025 | 15,829 | 15,829 | - | 5.4 | 86,268 | Common Stock |
| Michael F. Powell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 23,746 | 23,746 | - | - | Stock Option (Right to Buy) | |
| Kiran Mazumdar-Shaw | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 23,746 | 23,746 | - | - | Stock Option (Right to Buy) | |
| Christopher Bowden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 23,746 | 23,746 | - | - | Stock Option (Right to Buy) | |
| Jake Simson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 23,746 | 23,746 | - | - | Stock Option (Right to Buy) | |
| Scott Robertson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 23,746 | 23,746 | - | - | Stock Option (Right to Buy) | |
| Lara Meisner | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.45 per share. | 14 Mar 2025 | 79,146 | 79,145 | - | 5.5 | 431,346 | Common Stock |
| Lara Meisner | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 12.69 per share. | 14 Mar 2025 | 48,526 | 30,620 | - | 12.7 | 615,698 | Common Stock |
| Lara Meisner | Chief Legal Officer | Sale of securities on an exchange or to another person at price $ 13.24 per share. | 14 Mar 2025 | 30,620 | 0 | - | 13.2 | 405,513 | Common Stock |
| Lara Meisner | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 48,720 | 107,187 | - | - | Stock Option (Right to Buy) | |
| Lara Meisner | Chief Legal Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 30,246 | 67,119 | - | - | Stock Option (Right to Buy) | |
| Kiran Mazumdar-Shaw | Director, Ten Percent Owner | 12 Sep 2024 | 4,000,000 | 0 | - | - | Series Seed Redeemable Convertible Preferred Stock | ||
| Kiran Mazumdar-Shaw | Director, Ten Percent Owner | 12 Sep 2024 | 1,080,775 | 1,080,775 | - | 0 | Common Stock | ||
| Kiran Mazumdar-Shaw | Director, Ten Percent Owner | 12 Sep 2024 | 4,327,365 | 4,443,122 | - | 0 | Common Stock | ||
| Kiran Mazumdar-Shaw | Director, Ten Percent Owner | 12 Sep 2024 | 3,000,000 | 0 | - | - | Series Seed Redeemable Convertible Preferred Stock | ||
| Kiran Mazumdar-Shaw | Director, Ten Percent Owner | 12 Sep 2024 | 9,990,144 | 0 | - | - | Series Seed Redeemable Convertible Preferred Stock | ||
| Kiran Mazumdar-Shaw | Director, Ten Percent Owner | 12 Sep 2024 | 40,000,000 | 0 | - | - | Series Seed Redeemable Convertible Preferred Stock | ||
| Kiran Mazumdar-Shaw | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2024 | 23,746 | 23,746 | - | - | Stock Option (Right to Buy) | |
| Kiran Mazumdar-Shaw | Director, Ten Percent Owner | 12 Sep 2024 | 432,736 | 432,736 | - | 0 | Common Stock | ||
| Kiran Mazumdar-Shaw | Director, Ten Percent Owner | 12 Sep 2024 | 324,552 | 324,552 | - | 0 | Common Stock | ||
| Jake Simson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2024 | 23,746 | 23,746 | - | - | Stock Option (Right to Buy) | |
| Scott Robertson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2024 | 23,746 | 23,746 | - | - | Stock Option (Right to Buy) |